出 处:《中国药物与临床》2023年第6期359-365,共7页Chinese Remedies & Clinics
摘 要:目的探究脑电小波监测下右美托咪定在内镜逆行胰胆管造影(ERCP)中应用效果,基于生命体征、胃肠激素、认知功能等分析其最佳剂量选择。方法选取2022年1月至2023年1月嘉兴市第二医院102例拟行ERCP患者,分为高剂量组(34例)、中剂量组(34例)、小剂量组(34例),分别给予1.0μg/kg、0.7μg/kg、0.5μg/kg右美托咪定。统计3组围术期[入室时(T1)、右美托咪定输注完成后(T2)、进镜后(T3)、退镜后(T4)、清醒离室时(T5)]平均动脉压(MAP)、心率、动脉血氧饱和度(SpO_(2))、局部脑氧饱和度(rSO_(2))与术后1 d Ramsay评分,比较不同时间(术前、术后1 d、5 d)胃肠激素[胃动素(MLT)、胃泌素(GAS)]与心功能[肌钙蛋白I(cTnI)、肌酸激酶同工酶(CK-MB)],比较3组认知功能障碍发生率、病情相关指标及不良反应。结果T2、T3、T4时3组MAP、心率、rSO_(2)存在明显差异,且中剂量组各指标波动幅度小于小剂量组、高剂量组[T2时MAP:(80.8±6.6)mmHg、(86.6±6.9)mmHg、(81.1±5.6)mmHg;T2时心率:(66.6±4.5)次/min、(75.7±5.1)次/min、(66.2±5.8)次/min;T2时rSO_(2):(60.2±4.1)%、(68.5±4.7)%、(62.5±4.6)%](F=8.817、36.960、30.795)、[T3时MAP:(82.5±5.6)mmHg、(85.9±6.1)mmHg、(83.8±4.5)mmHg;T3时心率:(64.5±4.9)次/min、(75.1±4.8)次/min、(64.2±5.4)次/min;T3时rSO_(2):(61.6±4.5)%、(67.7±5.0)%、(62.2±4.6)%](F=3.311、51.809、17.454)、[T4时MAP:(70.7±4.1)mmHg、(82.6±4.8)mmHg、(74.6±5.6)mmHg;T4时心率:(67.7±5.3)次/min、(74.8±4.5)次/min、(68.1±4.7)次/min;T4时rSO_(2):(63.5±4.9)%、(68.0±5.1)%、(64.4±5.6)%](F=53.271、22.773、7.240)(P<0.05);术后1 d时,3组Ramsay评分比较差异均无统计学意义(U=1.909,P=0.591);术后1 d时3组血清MLT、GAS水平高于术前,且高剂量组血清MLT、GAS水平[(334±51)pg/ml、(29±5)pg/ml]低于中剂量组[(401±83)pg/ml、(32±5)pg/ml]和小剂量组[(471±96)pg/ml、(39±6)pg/ml](F=25.395、32.646,P<0.01);术后1 d时3组血清c TnI、CK-MB水平高于术前,Objective To explore the application effect of dexmedetomidine under EEG wavelet monitor-ing in endoscopic retrograde cholangiopancreatography(ERCP),and analyze the optimal dose selection based on vital signs,gastrointestinal hormones,cognitive function and other aspects.Methods A total of 102 patients with ERCP in our hospital from January 2022 to January 2023 were selected and divided into high-dose group(n=34),medium-dose group (n=34) and low-dose group (n=34) by randomized numerical table method, and were given 1.0 μg/kg, 0.7 μg/kg and 0.5 μg/kg dexmedetomidine, respectively. The perioperative mean arterial pressure (MAP), heart rate (HR), arterial oxygen saturation (SpO_(2)), local cerebral oxygen saturation (rSO_(2)) and Ramsay score 1 day after surgery were analyzed in the three groups [at entry (T1), after dexmedetomide infusion (T2), after admission (T3), after exit (T4), after exit (T5)] were counted. Gastrointestinal hormones [MLT, gastrin (GAS)] and cardiac function [troponin I (cTnI), myokinase isoenzyme (CK-MB)] were compared at different times (preoperative, post-operative 1 and 5 days), and the incidence of cognitive dysfunction, disease-related indexes and adverse reactions were compared among the three groups. Results There were significant differences in MAP, HR and rSO_(2) among the three groups at T2, T3 and T4, and the fluctuation range of each index in the medium-dose group was smaller than that in the low-dose group and high-dose group [MAP at T2: (80.8±6.6) mmHg, (86.6±6.9) mmHg, (81.1±5.6) mmHg;HR at T2: (66.6±4.5) times /min, (75.7±5.1) times /min, (66.2±5.8) times /min;rSO_(2) at T2: (60.2±4.1) %, (68.5±4.7) %, (62.5±4.6) %] (F=8.817, 36.960, 30.795), [T3 MAP: (82.5±5.6) mmHg, (85.9±6.1)mmHg, (83.8±4.5) mmHg;HR at T3: (64.5±4.9) times /min, (75.1±4.8) times /min, (64.2±5.4) times /min;rSO_(2) at T3: (61.6±4.5) %, (67.7±5.0) %, (62.2±4.6) %] (F=3.311, 51.809, 17.454), [T4 MAP: (70.7±4.1) mmHg, (82.6±4.8) mmHg, (74.6±5.6) mmHg;HR at T4: (67.7±5.3) times/min, (74.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...